Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Rupinder K. Kanwar,
Rakesh N. Veedu,
Richard L. Kennedy,
Jagat R. Kanwar.
Understanding the cellular target structure and thereby proposing the best delivery system to achieve sustained
release of drugs has always been a significant area of focus in biomedical research for translational benefits. Specific targeting
of the receptors expressed on the target cell represents an effective strategy for increasing the pharmacological efficacy
of the administered drug. Liposomes offer enhanced conveyance as a potential carrier of biomacromolecules such as
anti-cancer proteins, drugs and siRNA for targeting tumour cell death. Commonly used liposomal constructs for various
therapies are Doxil, Myocet, DepoCyt and Abraxanes. However, recent strategy of using multifunctional liposomes for
the sustained release of drugs with increased plasma residence time and monoclonal antibody-based targeting of tumours
coupled with imaging modalities have attracted enormous scientific attention. The ability of liposomes coated with specific
ligands such as Apo-E derived RGD R9 and Tat peptide, to reverse the conceptualisation of drug resistance and cross
the blood brain barrier, provides promising future for their use as an efficient drug delivery system. By outlining the recent
advancements and innovations in the established concept of liposomal drug delivery, this review will focus on the
multifunctional liposomes as an emerging novel lipid based drug delivery system.
Keywords: Liposomes, multidrug resistance, immunoliposomes and gene transfer.
Rights & PermissionsPrintExport